Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Histamine dihydrochloride topical - EpiCept Corporation

Drug Profile

Histamine dihydrochloride topical - EpiCept Corporation

Alternative Names: MaxDerm; MaxDerm gel; MX 1006; MX 8899

Latest Information Update: 24 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Maxim Pharmaceuticals
  • Class Antiepileptic drugs; Antimigraines; Antineoplastics; Antiparkinsonians; Antipsychotics; Antivirals; Behavioural disorder therapies; Ethylamines; Imidazoles; Neuroprotectants; Small molecules
  • Mechanism of Action Apoptosis inhibitors; Histamine H2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Burns; Conjunctivitis; Herpes simplex virus infections; Herpes zoster; Pressure ulcer; Radiodermatitis; Stomatitis

Most Recent Events

  • 09 Jan 2006 Maxim Pharmaceuticals has been acquired and merged into EpiCept Corporation
  • 01 Mar 2004 Phase-II clinical trials in Burns in USA (Topical)
  • 01 Mar 2004 Phase-II clinical trials in Conjunctivitis in USA (Topical)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top